2024
DOI: 10.1097/cnd.0000000000000484
|View full text |Cite
|
Sign up to set email alerts
|

What is in the Myopathy Literature?

Michael Isfort,
David Lacomis

Abstract: This update begins with a section on inflammatory myopathies covering inclusion body myositis in younger patients, the possibility of a pathogenic role for anti-cN1A antibodies, and a negative trial of arimoclomol in inclusion body myositis. The potential study of Janus kinase inhibitors in dermatomyositis is discussed as well as the possible role of targeted therapy for immune checkpoint inhibitor neuromuscular complications. Next, studies of disease-modifying or potential disease-modifying therapies for inhe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 46 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?